Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

"We are currently engaging with market participants," a spokesperson for South Africa's Competition Commission told Reuters, declining to provide details. USAID cuts put tuberculosis response in peril ...

Pfizer and BioNTech have convinced a U.S. Patent Office tribunal that two patents Moderna accused Pfizer-BioNtech of ...

The US Patent Trial and Appeal Board handed a massive victory to Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) on Wednesday, ...

Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...

A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price ...

Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and more.

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make ...